067630.Kq
The company operates in the pharmaceuticals industry, primarily generating revenue through the development, production, and sale of pharmaceutical products and related medical research.
Business. The company operates in the pharmaceuticals industry, primarily generating revenue through the development, production, and sale of pharmaceutical products and related medical research.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, primarily generating revenue through the development, production, and sale of pharmaceutical products and related medical research.
The company's capital structure is characterized by a debt-to-equity ratio of 0.54, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 0.58, suggesting limited short-term liquidity. The company's price-to-book ratio is 1.44, and its price-to-tangible-book ratio is also 1.44, indicating that the market values the company's equity at a premium to its book value. However, the company's negative net cash position after subtracting total debt raises concerns about its ability to meet short-term obligations.
Profitability metrics show significant underperformance relative to industry norms. The company reported a net loss of 99,794,375,250 KRW, with a return on equity of -0.3356 and a return on assets of -0.2087. These figures indicate that the company is not generating returns for shareholders or effectively utilizing its assets. The operating income was -24,479,408,760 KRW, and the gross profit was -494,412,460 KRW, further highlighting the company's operational challenges.
The company's revenue is not segmented by geographic regions or product lines in the available data, making it difficult to assess the concentration of its revenue sources. However, the negative operating cash flow of -22,933,098,770 KRW and the free cash flow of -120,626,115,320 KRW suggest that the company is not generating sufficient cash from operations to sustain its activities or fund growth initiatives.
The company's growth trajectory is negative, with a net loss and declining profitability. The available data does not provide specific outlook figures for the current or next fiscal year, but the company's financial performance indicates a challenging environment. The capital expenditure of -25,942,074,830 KRW suggests that the company is not investing in new projects or expanding its operations, which could further hinder its growth prospects.
The company's risk profile is elevated, with a medium liquidity risk and a low dilution risk. The negative net cash position after subtracting total debt is a key flag, indicating potential liquidity constraints. The company's valuation adjustments and risk factors suggest that investors should closely monitor its financial health and operational performance.
Recent events and filings do not provide specific details about the company's strategic initiatives or operational changes. The available data does not include recent transcripts or filings that could provide insight into the company's management decisions or market conditions.
- The company is experiencing significant financial losses, with a net loss of 99,794,375,250 KRW and negative returns on equity and assets.
- The company's liquidity position is weak, with a current ratio of 0.58 and a negative net cash position after subtracting total debt.
- The company is not generating positive cash flows from operations, with a negative operating cash flow of -22,933,098,770 KRW and a free cash flow of -120,626,115,320 KRW.
- The company's capital structure is moderately leveraged, with a debt-to-equity ratio of 0.54.
- The company's growth trajectory is negative, with no clear signs of improvement in profitability or cash flow generation.
- The company's risk profile is elevated, with a medium liquidity risk and a low dilution risk.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 067630.KQ Market data — financials · 2026-05-26